Wagener D J, de Mulder P H, Wils J A
Division of Medical Oncology, University Hospital Nijmegen St Radboud, The Netherlands.
Ann Oncol. 1994;5 Suppl 3:81-6. doi: 10.1093/annonc/5.suppl_3.s81.
The prognosis of locally advanced pancreatic cancer is poor (median survival 3-5 months). In view of the localized character of this disease several groups have explored the value of combined modality treatment. The conditions are that a good local treatment and an effective systemic treatment are available.
The results of irradiation and of chemotherapy in advanced disease are reviewed.
An overview of combined modality treatment has been given.
Results of combined modality treatment are superior to irradiation alone or to symptomatic treatment.
